ã³ããã¯ã¯ãã³ã®äœãæ¹

2023幎4æ5æ¥ãDNA/RNAã·ãŒã±ã³ã¹æ³ã®å°éå®¶ã§ããã±ãã³ã»ãã«ãŒãã³å士ããã³ããã¯ã¯ãã³ã«ã¯çްèç±æ¥ã®DNAãæ··å ¥ããŠãããããšãå ±åããããããããã埮éã©ããã§ã¯ãªããã¯ã¯ãã³ãã€ã¢ã«1æ¬ãããã«å«ãŸããæ žé žã®ãå®ã«20ïœ35ïŒ ããã®DNAãå ããŠãããšããããã¡ããæ¥µããŠå±éºãªéã§ããããã«ãŒãã³å士ã¯äžäœã©ã®ããã«ããŠãã®ããšãçºèŠããã®ãããŸãããã®çްèç±æ¥DNAãæ··å ¥ããŠããããšã§ãäžäœã©ã®ãããªå¥åº·ãªã¹ã¯ãèããããã ãããïŒ

ãã³ããã¯ã¯ãã³ã¯ïœRNAã¯ã¯ãã³ã ããšããããšã¯ã¿ãªãããåç¥ã§ããããã€ãŸããã³ãããŠã€ã«ã¹ã®ã¹ãã€ã¯ã¿ã³ãã¯ãäœãæ
å ±ãã³ãŒãããïœRNAãã¿ãªããã®äœã«æ³šå°ããŸãã现èå
ã«åã蟌ãŸããïœRNAã¯çްèã®ã¿ã³ãã¯ç£çæ©æ§ãå©çšããã¹ãã€ã¯ã¿ã³ãã¯ãç£çããããããŠãã®ã¹ãã€ã¯ã¿ã³ãã¯ã«å¯Ÿããå
ç«ãã§ããããå€çããæ¬ç©ã®ã³ãããŠã€ã«ã¹ãæ¥ããšãã«å
ç«ã§æéã§ããããã«ãããããããããã¶ã€ã³ã®ã¯ã¯ãã³ã§ãã
ããŠããã¡ã€ã¶ãŒãã¢ãã«ãã¯ãã®ã³ããã¯ã¯ãã³ãäžäœã©ã®ããã«è£œé ããŠããã®ã§ããããïŒ
ã¹ãã€ã¯ã¿ã³ãã¯è³ªãšããã®ã¯ååéãçŽ150 kDa(ãããã«ãã³)ãã£ãŠãããã¯ã¿ã³ãã¯è³ªã®ãªãã§ããªã倧ããã»ããªãã§ãããããšãã°ã¢ã«ããã³ã®ååéã§66.5kDaã§ããããã¢ã«ããã³ãããã¯ããã«å€§ããããããªã«ã倧ããååãååŠçã«åæããã®ã¯ãã£ããé£ãããã§ããããããäžçäžã®äººã«æ¥çš®ããããã«çæéã§å€§éã«äœããšãªãã°ãååŠçåææ³ã§ã¯çµ¶å¯Ÿã«äžå¯èœã§ããã ããã©ãããã®ãïŒå€§è
žèã䜿ããŸãã
倧è
žèã®éºäŒåã«ã¹ãã€ã¯ã¿ã³ãã¯ã®DNAãæ¿å
¥ããŸãã倧è
žèã¯ãç°å¢ãæŽãã°ãåã
ã²ãŒã ã§å¢ããŠãããŸãããã倧éã®ãã¹ãã€ã¯ã¿ã³ãã¯DNAä¿æå€§è
žèããäœãããšãã§ããŸãããã®å€§è
žèããäžæã«DNAã ããåãåºããããããRNAãäœãã倧éæã«èšããšããããããµãã«ã¹ãã€ã¯ã¿ã³ãã¯ã®ïœRNAãäœã£ãŠããŸãã

ããã¡ãã£ãšè©³ããèšããšããããã倧è
žèã®éºäŒåã¯ãæ¬äœãšãèšãã¹ãæè²äœDNAãšããã©ã¹ãããšããç°ç¶DNAããããŸãããã©ã¹ããã¯çåã«å¿
é ã§ã¯ãªãããã©ããããšãã°è¬å€èæ§ã«é¢ããæ©èœãªããã¯ãããæ
ã£ãŠããŸãã倧è
žèã现èåè£ãããšãåšçްèã«ã¯æè²äœDNAããã©ã¹ããDNAã®äž¡æ¹ãåãç¶ãããŠãããŸãããã ããããååŠåæãšã¯éãã倧è
žèã®æ°ãŸãããªãšããã§ããšãã©ããã©ã¹ãããæ¬¡äžä»£ã«åãç¶ãããªããšãããããŸãããã£ããã¹ãã€ã¯ã¿ã³ãã¯DNAãçµã¿èŸŒãã ãã©ã¹ãããªã®ã«ããããåãç¶ãã§ãããªããã°ã墿®ãããæå³ããããŸãããããã§ããã¡ã€ã¶ãŒãã¢ãã«ã䞡瀟ãšãããã®ãã©ã¹ããã«æçå€(ã«ããã€ã·ã³)èæ§ã®éºäŒåãçµã¿èŸŒãã§ããŸãã倧è
žèãå¹é€ããå¯å€©å¹å°ã«ã«ããã€ã·ã³ãæ··ããŠããã°ããããã©ã¹ãããæ¬¡äžä»£ã«åãç¶ããæãã倧è
žèã¯ãããã§ãããã«éžå¥æ·æ±°ã§ããŸãã
ååéã®å€§è
žèã墿®ãããããããã®èããŸãšããŠç Žå£ãããã©ã¹ããDNAãä»ã®èäœæåããåé¢ç²Ÿè£œããŸãã
ããã«å¶éé
µçŽ ãæ·»å ããŠãç°ç¶ã®ãã©ã¹ãããçŽç·ç¶ã«ããŸããå¶éé
µçŽ ããã¡ããã©ã¹ãã€ã¯ã¿ã³ãã¯è³ªãã³ãŒãããéºäŒåè¿ãã®ç¹å®ã®éšåã§ãDNAååãåæããæ Œå¥œã§ãããã®æäœã«ãããã茪ã£ãããããã¢ãã«ãªãããã§ãã
次ã«RNAããªã¡ã©ãŒãŒã䜿ã£ãŠãDNAããRNAãäœããŸãããã¡ã€ã¶ãŒãã¢ãã«ã䞡瀟ãšããT7 RNAããªã¡ã©ãŒãŒãšããããªã¡ã©ãŒãŒã䜿ã£ãŠããŠããã®é
µçŽ ããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®éºäŒåã®ããã¢ãŒã¿ãŒé
åã«çµåããã
Transcription | RNA synthesis | RNA polymerase - YouTube
åç»ã§èŠããšã€ã¡ãŒãžããããã§ããDNAãé³åãšããŠãããã«å¯Ÿå¿ããå¡©åºã次ã
ãšã¯ãŸã£ãŠãã£ãŠãRNAã玡ãåºãããŠãããŸãã
ããã§ãªãããŠãã工倫ãšããŠãå¡©åºãšããŠå€©ç¶ã®ãŠãªãžã³ã§ã¯ãªããåæã®ã¡ãã«ã·ã¥ãŒããŠãªãžã³ã䜿ã£ãŠããŸãããã2幎åã«ãªããŸããã2021幎6æååŽçã«ãæ¥çš®äžæ¢ãæ±ããå顿žããæåºããåŸã®èšè
äŒèŠã§ãåã¯ãã®ç¹ã«è§ŠããŠããŸããã

æ®éã®RNAã¯æ¥µããŠè匱ã§ãããšãã°åŸæ¶²ã«è§Šããã ãã§ãããã«åè§£ãããŠããŸããããããŠãªãžã³ã«äžå·¥å€«ããŠã¡ãã«ã·ã¥ãŒããŠãªãžã³ã«ããã ãã§ãé£åè§£æ§ã®RNAã«ãªããããã¯ãã¡ã€ã¶ãŒç€Ÿãã¢ãã«ã瀟ãäž¡æ¹ã«äœ¿çšãããŠããæè¡ã§ãã
ããããŠå®æããïœRNAã¯ã泚å
¥ãããçç©ã®çްèå
ã«åã蟌ãŸãããªããœãŒã ã«ã¹ãã€ã¯ã¿ã³ãã¯ã®ç£çãæç€ºããããšãã§ããŸãã
ãããããã®æ®µéã®æº¶æ¶²ãã宿åããšåŒãã§ã¯ãããŸããã倧è
žèç±æ¥ã®é³åDNAã倧éã«æ®åããŠããããã§ãããã®DNAããäžãäžäœå
ã«æ³šå
¥ããããããªããšããã£ãŠã¯å€§æšäºã§ãã
ãã®DNAãé€å»ããããã«ãDNaseãšããå¥ã®é
µçŽ ã䜿ããŸããããã«ãã£ãŠDNAãå°ããªæçã«åè§£ãé€å»ããæ¿Ÿéãªã©ã§ç²Ÿè£œããŸããããã«ãïœRNAãè質ãšçµåãããŠè質ããç²å(LNP)ã«ããŠããã现èã«åã蟌ã¿ããããããããããŠåããŠãïœRNAã¯ã¯ãã³ã宿ããŸãã
ãããåé ã§ãè¿°ã¹ãéãããã«ãŒãã³å士ãã³ããã¯ã¯ãã³(äºäŸ¡ã¯ã¯ãã³)ã®ãã€ã¢ã«ãå®éã«åæãããšãããå
¥ã£ãŠããŠã¯ãããªãã¯ãã®çްèç±æ¥ã®DNAã倧éã«èŠã€ãããŸããã
ã©ã®ããã«ããŠèŠã€ããã®ããæè¡çãªæ¹æ³ã«ã€ããŠããã«ãŒãã³å士ã以äžã®èšäºã§è§£èª¬ããŠããã
McKernan, K. (2023) Deep sequencing of the Moderna and Pfizer bivalent vaccines identifies contamination of expression vectors designed for plasmid amplification in bacteria.
ã¯ã¯ãã³ã®ãªãã«ã¯å°ããªDNAæçã倧éã«ãããããã«ãå®å
šé·ïœRNAãããããã«å€§ããªRNAãŸã§çºèŠããããšããã
DNAãæ··å
¥ããŠããããšã¯åãã£ã(宿§ç)ããã«ãŒãã³åå£«ãæ¬¡ãªãç ç©¶ãšããŠãä»åŸã¯ãã®DNAæ±æã®å®éåã«åãçµãã ã
McKernan, K. (2023) Pfizer and Moderna bivalent vaccines contain 20-35% expression vector and are transformation competent in E.coli.
ã¯ã¯ãã³å
ããçºèŠãããDNAã倧è
žèã«åã蟌ãŸãããšãããã¡ããšæ©èœãããã©ãã調ã¹ãããããšããã®DNAããšãããã 倧è
žèã¯ãã«ããã€ã·ã³ãå«ãå¹å°ã§çåèœåã瀺ããããããäœãæå³ãããïŒ
ã¯ã¯ãã³ã«ã¯æçå€èæ§ãã©ã¹ããDNAãå«ãŸããŠããããããåã蟌ãã 倧è
žèã«èæ§ãäžãããšããããšã§ããã°ã£ã¡ãæ©èœããŠããDNAã ã£ããšããããšã§ããæãããããšã«ã
ãªããã®çŸè±¡ã¯ãã¡ã€ã¶ãŒç€Ÿè£œã¯ã¯ãã³ãã¢ãã«ã瀟補ã¯ã¯ãã³ã®äž¡æ¹ã§èгå¯ãããã
ããã«ãã®å®éšã§æ³šç®ãã¹ãããšãšããŠã倧è
žèãåã蟌ãã®ã¯ãçŽéç¶ã®DNAã§ã¯ãªããç°ç¶ãã©ã¹ããã ãã ãšããããšã§ããã€ãŸãããã®ã¯ã¯ãã³ã«ã¯ç°ç¶ãã©ã¹ãã(ãšçŽéç¶ãã©ã¹ããã®äž¡æ¹)ãå«ãŸããŠããŸãã
äžäœäººéã®çްèããã®ãã©ã¹ãããåã蟌ãã ãã©ããªãã®ãïŒ
æçå€ãå¹ãã«ãããªããããããªããŸã ãããã¹ãã€ã¯ã¿ã³ãã¯ãå»¶ã
ç£çãç¶ãããšããã°ããã
ãã«ãŒãã³å士ã¯ãããã«å®éPCRæ³ã䜿ã£ãŠã¯ã¯ãã³ãæ€æ»ãããšãããDNA嫿éã¯EMA(欧å·å»è¬åå±)ã®å¶éå€ã®18ïœ70åãè¶
ããé«å€ã ã£ããMcKernan, K. (2023) DNA contamination in 8 vials of Pfizer monovalent mRNA vaccines.
ã³ããã¯ã¯ãã³ã«å«ãŸããDNAã¯ãïœRNAåæ§ãè質ããç²åã«ãã£ãŠçްèå
ã«éã³èŸŒãŸãããã§ã¯ãã®å¯¿åœã¯ïŒãã€åè§£ããã®ãïŒãããã¯ãã€ãŸã§æ®åããã®ãïŒ
ãã§ã«å
è¡ããè€æ°ã®ç ç©¶ãããã¹ãã€ã¯ã¿ã³ãã¯è³ªèªäœãããããã³ãŒãããæ žé
žããæ³šå°åŸå°ãªããšãæ°é±éããæ°ãæã«ããã£ãŠè¡æµãæ§ã
ãªèåšã§æ€åºãããŠããã
ãªãããããªã«ãé·ãæ®åããŠããã®ãïŒ
å®ã¯ããã¯å€ãã®ç§åŠè
ã«ãšã£ãŠé·ããã®çåã§ãããã修食ãŠãªãžã³ã䜿ã£ãé·å¯¿åœã®ïœRNAã§ãããšã¯ãããæ°ãæãã¹ãã€ã¯ã¿ã³ãã¯ãç£çããç¶ããã®ã¯äžäœãªããªã®ãïŒã
ãããä»åã®ãã«ãŒãã³å士ã®çºèŠã«ããããã®çç±ã説æå¯èœã«ãªããŸããã
ã¯ã¯ãã³ã«å«ãŸãããã©ã¹ããDNAã®ååšã§ãããã©ã¹ããã¯ç°ç¶äºééDNAã§æ¥µããŠå®å®ã§ãããäœçްèå
ã«ååšãç¶ããŸãããããŠãã®ãã©ã¹ããäžã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªéºäŒåãã现èå
ã®RNAããªã¡ã©ãŒãŒã«ãã£ãŠïœRNAã«è»¢åãããäœå
ã§å»¶ã
ã¹ãã€ã¯ã¿ã³ãã¯ãç£çãããããšã«ãªããŸãã
ããã«ããã²ãšã€ããã«ãŒãã³å士ã屿§ããŠãããªã¹ã¯ããããŸããå士ããã¡ã€ã¶ãŒç€Ÿè£œã¯ã¯ãã³ã®å«ãŸãããã©ã¹ãããåæãããšãããSV40ãŠã€ã«ã¹(ã·ãã¢ã³ãŠã€ã«ã¹ïŒäŸµå
¥ãã现èãçåããã)ç±æ¥ã®ããã¢ãŒã¿ãŒãçºèŠãããŸããã
ã¯ã¯ãã³æ¥çš®è
ã«æ¥éé²è¡ããç(ããããã¿ãŒãç)ãå¢å ããŠããããã¯ã¯ãã³ã«å«ãŸããSV40ããã¢ãŒã¿ãŒããã®åå ãããããªãã
现èå
ã«åã蟌ãŸãããã©ã¹ããããããã«æè²äœã«ãŸã§çµã¿èŸŒãŸããã°ã©ããªããïŒãã®çްèãåè£ããéãåå«ã®çްèã«ã次ã
åãç¶ãããŠããããšã«ãªããæè²äœãžã®çµã¿èŸŒã¿ã¯ãéºäŒæ¯æ§ãã®ãã®ã§ãã
å®ã¯çްèç±æ¥ã®ãã©ã¹ãããåºä¹³é¡çްèã®æè²äœDNAã«çµã¿èŸŒãããšãå¯èœã§ããããšã¯ããã§ã«1982幎ã«å®èšŒãããŠããŸããã
Southern, P.J. and Berg, P. (1982) Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J. Mol. Appl. Genet. 1:327-41
ãã©ã³ã¹ãã§ã¯ã·ã§ã³(æ žé
žãåç©çްèå
ãžå°å
¥ããããš)ãšãããä»ãååçç©åŠã®åéã§ã¯åœããåã«çšããããŠããææ³ã§ãã
ãã¡ã€ã¶ãŒè£œã¯ã¯ãã³ã®ïœRNAãåã蟌ãã ããè现èãããã¹ãã€ã¯ã¿ã³ãã¯ã®DNAã³ããŒãæ€åºããããšããç ç©¶ããããŸãã(Alden et al)ãåã®éå»èšäºã§ãäœåºŠã玹ä»ããããšããããŸãã

ãã®ç ç©¶ãè¡ã£ãåœæãAldenãã¯ãã®ã¯ã¯ãã³ã«DNAãå«ãŸããŠãããšã¯æã£ãŠããããçŽç²ãªïœRNAãå«ãŸããŠãããšããä»®å®ã®ããšããã®èгå¯çµæããåæïœRNAã现èå ã§é転åãèµ·ããã蚌æ ã§ããããšèããŸãããããã¯ãã£ãšããªè§£éã§ãããã®ãããªé転åã¯ç¢ºãã«åççã«èµ·ããåŸãŸããããããããã«ãŒãã³å士ãã¯ã¯ãã³ãã€ã¢ã«ãã倧éã®DNAãçºèŠããä»ãšãªã£ãŠã¯ããã®çŸè±¡ã説æããã®ã«é転åé µçŽ ãæã¡åºãå¿ èŠã¯ãããŸããããã£ãšåçŽã«ãã¯ã¯ãã³å«æã®DNAãåã蟌ãŸããããã§å»¶ã ã¹ãã€ã¯ã¿ã³ãã¯ãäœã£ãŠãããšèããããŸãã
é·ãèšäºã«ãªã£ãŠããŸããŸãããå 容ããå ããŠèªã¿ã«ããããšæããŸãããããä»åã®ãã«ãŒãã³å士ã®çºèŠã¯ãã³ããã¯ã¯ãã³ã®æå®³æ§(æ¥çš®è ã®éºäŒåãå€åããŠããããšãçºçæ§ãå ç«ç°åžž)ãæ ¹æ¬çãçµ±äžçã«çè§£ããã«ã®ã«ãªããããããŸããã
ã³ããã¯ã¯ãã³æçµç« çµããã®å§ãŸããã²ãã è§£æãããç ç©¶è ãDNAã®æ··å ¥ãçºèŠããããäžå¯è§£ãããå 容ãã³ãã¯ã¯çæã®æéèŠå±é¢ãèªãäž¡å çã®ç·æ¥å¯Ÿè«ãæ¡æ£ããé¡ãããŸãïŒhttps://t.co/W33GnEsAZk
â Trilliana è¯ (@Trilliana_z) April 16, 2023
èå·å
çãšæäžå
çã®å¯Ÿè«
é£ããå
容ã ãã©ãåã®äžèšã®èª¬æãèŠãåŸã ãšå°ãçè§£ãããããªãããã
ã³ããã¯ã¯ãã³ã«å€§è
žèç±æ¥ã®ãã©ã¹ãããå«ãŸããŠããŠããã®å®å®æ§ã®é«ãäºééãã©ã¹ãããæ¥çš®è
ã®äœå
ã«åã蟌ãŸããããã®ããã§ãäœå
ã§å»¶ã
ã¹ãã€ã¯ã¿ã³ãã¯ãç£çãããã
åã®èšåºã§ã¯ãã·ã§ãã£ã³ã°ã«æ©ãæ£è
ãå€ãæ¥é¢ãããŸããããæ£è
ãèšã£ãŠããŸãããããããã5æãã6åç®ãå§ãŸããŸãããç§ã®è·å Žã§ã¯ã¿ãªãã3åæ¥çš®ãšã4åæ¥çš®ãŸã§ã§ãã4åæ¥çš®ããŠããããæ°ãæçµã¡ãŸããããããäººã¯æ¬åœã«ãããã§ãããã£ãšããããŸãŸã§ãããªããšãããããããã人ãã¡ã£ãŠãããéºäŒåãå€ãã£ãŠããŸã£ãŠãããããªãã§ããïŒã
ãã«ãŒãã³å士ã®çºèŠãèžãŸããŠèãããšããã®æ£è
ã®çŽæã¯æ£ããã£ãããã§ãã
ã³ããã¯ã¯ãã³ã®äœããããè§£æããããšã¯ãã¯ã¯ãã³åŸéºçãã·ã§ãã£ã³ã°ã®æ²»çã«ãã€ãªãã£ãŠããŸããããããæå³ã§ããã«ãŒãã³å士ã®çºèŠã®æçŸ©ã¯å€§ããããã©ãããã
éºäŒåãå€åããŠããŸã£ãŠãããšããäºå®ãããã»ã©æç¢ºã«çªãã€ããããŠã¯ãæ¥çš®è
ã®ç«ã€ç¬ããªããæ¥çš®è
ãšæªæ¥çš®è
ã®åæãç
œããããªãããã§ããªããšãè€éãªæ°æã¡ãªãã ãã©ããã